[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546951":3},{"organization":4,"outcomesModule":7,"designInfo":35,"detailedDescription":41,"studyPopulation":34,"armGroups":42,"interventions":49,"overallOfficials":55,"centralContacts":34,"locations":59,"responsibleParty":86,"collaborators":34,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":34,"eligibilityCriteria":95,"healthyVolunteers":91,"sex":96,"minAge":97,"maxAge":34,"enrollmentInfo":98,"targetDuration":34,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":34,"overallStatus":62,"whyStopped":34,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Mayo Clinic","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":23,"otherOutcomes":34},[9,13,17,20],{"measure":10,"description":11,"timeFrame":12},"Headache relief in 2 hours","Percentage of participants who have meaningful headache relief within 2 hours of administering zavegepant","2 hours",{"measure":14,"description":15,"timeFrame":16},"Headache relief in 4 hours","Percentage of participants who have meaningful headache relief within 4 hours of administering zavegepant","4 hours",{"measure":18,"description":19,"timeFrame":12},"Functional disability level in 2 hours","Percentage of participants with functional disability level of normal or mildly impaired within 2 hours of administering zavegepant.",{"measure":21,"description":22,"timeFrame":16},"Functional disability level in 4 hours","Percentage of participants with functional disability level of normal or mildly impaired within 4 hours of administering zavegepant.",[24,28,31],{"measure":25,"description":26,"timeFrame":27},"Adverse events","Percentage of participants and treated migraine attacks with treatment emergent adverse events","Approximately 24-32 weeks",{"measure":29,"description":30,"timeFrame":27},"Serious adverse events","Percentage of participants and treated migraine attacks with serious treatment emergent adverse events",{"measure":32,"description":33,"timeFrame":27},"Discontinuation due to adverse events","Percentage of participants who discontinue zavegepant due to adverse events",null,{"allocation":36,"interventionModel":37,"interventionModelDescription":34,"primaryPurpose":38,"observationalModel":34,"timePerspective":34,"maskingInfo":39},"NA","SINGLE_GROUP","TREATMENT",{"masking":40,"maskingDescription":34,"whoMasked":34},"NONE","This is a phase IV, open-label, prospective, longitudinal clinical trial of intranasal zavegepant 10 mg, a CGRP receptor antagonist, for the acute treatment of migraine attacks amongst individuals who are concomitantly taking stable doses of CGRP targeting migraine preventive treatment (atogepant, eptinezumab, erenumab, fremanezumab, galcanezumab, rimegepant). The effectiveness and tolerability of zavegepant will be assessed in this specific participant population. Participants who are not already taking a CGRP-targeting migraine preventive treatment but who meet criteria for migraine prevention according to their clinician's discretion, will have the option to start rimegepant 75 mg every other day (qod) for two months. After two months, continued eligibility for participation in the clinical trial of zavegepant will be assessed. Those receiving rimegepant for migraine prevention through their participation in this study will have the option to receive rimegepant for up to 32 consecutive weeks.",[43],{"label":44,"type":45,"description":46,"interventionNames":47},"Zavegepant Treatment","EXPERIMENTAL","Participants will receive zavegepant to treat up to 8 migraine attacks over 24 weeks.",[48],"Drug: Zavegepant",[50],{"type":51,"name":52,"description":53,"armGroupLabels":54,"otherNames":34},"DRUG","Zavegepant","10 mg intranasal",[44],[56],{"name":57,"affiliation":5,"role":58},"Todd Schwedt, MD","PRINCIPAL_INVESTIGATOR",[60],{"facility":61,"status":62,"city":63,"state":64,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"Mayo Clinic in Arizona","RECRUITING","Phoenix","Arizona","85254","United States","US",{"type":69,"coordinates":70},"Point",[71,72],-112.07404,33.44838,{"lat":72,"lon":71},[75,80,84],{"name":76,"role":77,"phone":78,"phoneExt":34,"email":79},"Michael R Leonard","CONTACT","480-342-2908","Leonard.Michael@Mayo.edu",{"name":81,"role":77,"phone":82,"phoneExt":34,"email":83},"Dani SMith","480-342-6524","Smith.Dani@mayo.edu",{"name":85,"role":58,"phone":34,"phoneExt":34,"email":34},"Todd J Schwedt, MD",{"type":58,"investigatorFullName":87,"investigatorTitle":88,"investigatorAffiliation":5,"oldNameTitle":34,"oldOrganization":34},"Todd J. Schwedt","Principal Investigator","100546951","phase-4-effectiveness-and-tolerability-of-zavegepant-for-acute-migraine-treatment-among-those-using-cgrp-targeting-preventive-medications-100546951",false,"NCT06401642","Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications","A Study to Assess Effectiveness and Tolerability of Zavegepant as an Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications.","Inclusion Criteria\n\n* Meets International Classification of Headache Disorders 3 (ICHD-3) diagnostic criteria for migraine with or without aura\n* At least 18 years of age\n* 2- 8 migraine attacks per month\n* Participants should be on a calcitonin gene-related peptide (CGRP)-targeting preventive migraine medication on a stable dose for a) ≥2 months prior to zavegepant treatment if an oral gepant or a monoclonal antibody (mAb) injected monthly, or b) at least two treatments if a mAb injected each 3 months.\n\n  * Atogepant\n  * Eptinezumab\n  * Erenumab\n  * Fremanezumab\n  * Galcanezumab\n  * Rimegepant\n\nExclusion Criteria\n\n* Primary headache disorders other than migraine (tension-type headache days are allowed)\n* History of hypersensitivity reaction to zavegepant or to any of the components of zavegepant\n\nEligibility Notes\n\n* Participants may have either episodic or chronic migraine.\n* Prior use of zavegepant and other gepants is permitted.\n* Participants can be using migraine preventive medications\u002Ftreatments in addition to the CGRP-targeting preventive treatment, as long as those treatments have been stable for at least two months at the time of enrollment.\n\nAdditional Eligibility Criteria for Participants to Start on Rimegepant for Migraine Prevention\n\nInclusion Criteria:\n\n• Must have 4 or more migraine days per month, on average, during the 2 months prior to the Screening Visit, according to participant self-report.\n\nExclusion Criteria\n\n• History of hypersensitivity reaction to rimegepant or to any of the components of rimegepant.","ALL","18 Years",{"count":99,"type":100},200,"ESTIMATED","INTERVENTIONAL",[103],"PHASE4","Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of migraine attacks amongst participants who are using calcitonin gene-related peptide (CGRP) migraine preventive treatments.",[106],"Migraine","2026-09-14",{"date":109,"type":110},"2026-09-17","ACTUAL",{"date":112,"type":110},"2024-03-22",{"date":114,"type":100},"2027-03",{"name":5,"class":6},1]